- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.02. | Bayer and celebrity chef keep diners in the dark to shed light on heart health | ||
| 13.02. | Novartis to seek full FDA approval for IgAN drug Vanrafia despite missing ph. 3 kidney function goal | ||
| 13.02. | PTC shuts down FDA approval bid for troubled Duchenne med Translarna | ||
| 12.02. | Amid Wegovy pill's flying start in US, Novo CEO eyes Ireland expansion for supply overseas: Bloomberg | ||
| 12.02. | AbbVie mounts fresh IRA legal challenge over Botox's inclusion in latest drug pricing negotiations list | ||
| 12.02. | Alnylam turns profitable even as Amvuttra ATTR revenue disappoints in Q4 | ||
| 12.02. | Supreme seasons creative agency portfolio with Broth buyout | ||
| 12.02. | CSL's bleak earnings report helps explain why it made CEO switch | ||
| 12.02. | Sanofi ousts Paul Hudson after 'bumpy ride', poaches Merck KGaA CEO to lead the French pharma | ||
| 11.02. | J&J's Tremfya roars into 2026 with massive TV ad spend, trailed by AbbVie's Rinvoq and Skyrizi | ||
| 11.02. | GSK, Teva quietly settle Coreg 'skinny label' dispute after long legal back-and-forth | ||
| 11.02. | Despite tempered sales outlook, Gilead positions Yeztugo to dominate HIV PrEP market as sales surge for older Descovy | ||
| 11.02. | China indicts AstraZeneca and former exec Leon Wang over data, trade charges | ||
| 11.02. | Merck pushes Keytruda across the FDA finish line for its first ovarian cancer nod | ||
| 10.02. | NIH stops Xarelto arm of stroke trial due to safety, lack of efficacy | ||
| 10.02. | Taiwan's PharmaEssentia to build $46M manufacturing plant in Puerto Rico | ||
| 10.02. | AstraZeneca sets sights on 25+ blockbusters by 2030 to fuel $80B revenue ambition | ||
| 10.02. | As Jakafi approaches generic competition, Incyte counts more on Opzelura | ||
| 10.02. | FDA untitled letters target Novo's 1st Wegovy pill ad and spots from argenx, Sobi | ||
| 10.02. | Moderna inks long-term pact with Mexico to bolster local mRNA vaccine supply | ||
| 10.02. | Under pressure, CSL chief hits exit as former Seqirus exec steps into interim role | ||
| 09.02. | Pharma's 2026 Super Bowl ads: Novo's Wegovy pill spot is engagement MVP, while Novartis scores 'likeability' touchdown | ||
| 09.02. | Novartis CEO pay soars 30% to $32M following record-breaking 2025 performance | ||
| 09.02. | Bristol Myers and Evinova pen global development partnership | ||
| 09.02. | Otsuka awareness campaign urges HCPs to see 'All of ADHD' |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.